Group Purchasing |  Utilize Iron Mountain for Document Management, Storage and Shredding
SoCalBio's Group Purchasing Committee is pleased to announce that Iron Mountain was selected to provide member companies with document management, storage and shredding services at significant discounts. To learn more and sign up, contact Jared
Jerotz, Sales, Data Protection, Iron Mountain at jared.jerotz@ironmountain.com(must be a SoCalBio member company or organization) |
Join SoCalBioJoin well-known entrepreneur Alfred Mann and other SoCalBio leaders to promote the biotech and device industries in the Greater Los Angeles Metro Area for job creation and overall economic growth. |  |
Looking for Experts to Help You Craft PR, Communicaton and Branding Strategies?  | |
Recommended Events Personalized Medicine Today and Tomorrow
Date: June 9, 2009
Time: 5:30 p.m. - 8:00 p.m. Pfizer La Jolla
Building CB4 Patio
10646 Science Center Drive
San Diego, CA --------------------------------------
| 
Register Now |
Enhance your Career BIOTECH DEMYSTIFIED The Science Behind the Business
June 8-10, 2009
Rady Center for Executive Development, UC San Diego
San Diego, CA
| MOMENTUM WEEKEND FOR WOMEN IN LIFE SCIENCES June 11-14, 2009 Keck Graduate Institute Learn more LIFE SCIENCE
ENTREPRENEUR'S
BUSINESS LAW
PRIMER
Thomas Jefferson School of Law, San Diego |
|
| 
| June 2, 2009 |
| Thanks to Lead SoCalBio Sponsor |  |
RSVP Now for SoCalBio Events | - June 4, 11 to 2
- June 12, 7:30 am - 5:30 pm
June 16, 10:00 am - 4:00 pm - June 19, 11 to 2
June 25, 7:00 - 9:30 am September 17, 7:00 am - 7:00 pm
|
Thanks to Attendees of the May 28 Networking Forum at USC | 
|
Biotechnology and the Economic
Downturn | |
How the Changing Landscape May Change Biotech's Business Models Going Forward
In its annual report on the biotechnology industry, Ernst & Young warns that the global financial crisis threatens to render the business models that have driven the sector to date unsustainable. The funding drought is placing these business models that fueled biotechnologies growth since its inception under unprecedented strain, the reports says. But emerging trends will likely open the way for new and more sustainable ways of funding drug development .... Click here to order the report |
| Funding | Spectrum Raises $20 Million The Irvine-based Spectrum Pharmaceuticals Inc. said last Friday that it received $20 million from three institutional investors as part of a registered direct stock offering. Proceeds from the offering will be used for general corporate purposes, the company said.... Read more Mann's Quallion Goes After the Stimulus Money Quallion of Sylmar is one of 50 battery companies that are applying for a piece of the stimulus money available for electric-vehicle batteries. Quallion is a small company that is 90% owned by Los Angeles biomed entrepreneur Alfred Mann.... Read more |
| Clinical Studies | Devax Receives IDE Approval to Commence Pivotal Study of its AXXESS Biolimus A9 Eluting Bifurcation Stent System "This is the first IDE approval of a drug eluting stent specifically designed for use in coronary bifurcations," said Devax's President & CEO Jeff
Thiel. "We have focused our attention on being the first to market in the United States with a dedicated DES, and this is an important step toward that goal" .... Read more New Data Demonstrate Anti-Tumor Activity for ABRAXANE Combination Chemotherapy Regimen in Patients with Metastatic Pancreatic Cancer
Data from ongoing phase I/II clinical study by Abraxis Bioscience (Los Angeles) evaluating ABRAXANE for the treatment of patients with advanced metastatic pancreatic cancer demonstrate that the combination of ABRAXANE and gemcitabine is well tolerated and has substantial antitumor activity in patients with pancreatic cancer ... Read more Xencor Presents Preliminary Phase I Data on XmAb2513 Antibody for Lymphomas at 2009 American Society of Clinical Oncology Annual Meeting XmAb2513, an antibody drug candidate developed by Xencor (Monrovia) based on proprietary antibody engineering technology, was well tolerated in patients who had a median of six prior lines of cancer treatment. The maximum tolerated dose has not yet been reached, as patients continue to do well on therapy with XmAb2513.... Read more |
| NDAs | ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis Last November, ISTA (Irvine) filed its NDA with the FDA for
Bepreve. ISTA expects a standard review of ten months and has been given a PDUFA decision date of 9/12/09 for the FDA to complete its review of its pending.... Read more |
| Relocation | DaVita to Move Headquarters from California to Denver DaVita Inc., which operates 1,400 kidney treatment centers nationwide, says it will move its corporate headquarters from El Segundo, Calif., to Denver. Chairman and CEO Kent Thiry said
the company expects the move to save millions of dollars. He also cited Denver's central location and quality of life, and DaVita's growing business in the region.... Read more |
About SoCalBio |  SoCalBio membership links you to partners, contract manufacturers, regulatory and legal experts, and policy makers. The organization's programs help emerging biotech and medical device companies grow. Membership is affordable -- as low as $500 -- and offers access to networking opportunities, advocacy, discounts through our group purchasing program group purchasing program and other benefits you simply can't find elsewhere ... Join SoCalBio |
| Editor: Ahmed A. Enany Southern California Biomedical Council (SoCalBio) |
| |
|
